Pfenex Still Waiting For FDA Teriparatide Equivalence Designation
US-Based Firm Is Confident Coronavirus Will Not Impact Prospects
Hailing the past year as a "transformational period" in which "we moved towards being a business with an FDA-approved product nearing commercialization," Pfenex ended 2019 in profit and with cash in the bank, as it eyes the potential for a monopoly in the follow-on teriparatide market.
